Home / Resources / 6 Essential Strategies for Small Biotechs to Thrive in a Challenging Market

6 Essential Strategies for Small Biotechs to Thrive in a Challenging Market

Infographic
Clinical
6 Essential Strategies for Small Biotechs to Thrive cover

Small biotechs may be under pressure, but they’re also uniquely positioned to innovate, adapt, and lead.

Yet, amid these headwinds, there are also powerful tailwinds — emerging technologies, global trial opportunities, and a renewed focus on innovation — that can help small biotechs not only survive but thrive.

Download the infographic to learn more.


Related products
Supporting across your entire product lifecycle
リアルワールドデータソリューション
3億人の米国市民に関する多様でトークン化されたリアルワールドのデータセットを活用して、臨床試験の計画と実施を患者中心の視点で行ってください。
Citeline consulting expert providing actionable insights on feasibility activities.
サービスとしての実現可能性（FaaS）
最先端の分析ソリューションは、臨床プロセスを加速し、成功を予測することができます。
Citeline subscriber exploring the diversity feasibility using Global Patient Insights.
Global Patient Insights
Enabling sponsors to optimize investigator selection and hit diversity goals faster

Related resources

The Growing Pains of Chinese Biotech
NOV 08, 2023
Article
商業化支援サービス

The Growing Pains of Chinese Biotech

China’s emergence from API manufacturer to innovator, fueled by domestic funding and talent, has been one of the most notable trends of the last decade.

Disclosure as a Service Case Study resource card thumbnail
DEC 01, 2019
サービス活用事例
薬事規制関連支援サービス

Small But Growing Biotech Manages Disclosure, Maintains Compliance, & Keeps Its Promise to Patients

While most large study sponsors place a high priority on transparency, smaller sponsors are not as quick to jump on the bandwagon. This one’s an exception.

Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial
Use Case
Patient Engagement & Recruitment

Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial

A biotech need to rapidly meet diversity/inclusion goals for a high-profile Phase III COVID-19 trial. Citeline Connect helped the sponsor recover from a 72% decline in diversity-focused randomizations, delivering 20-25% of daily randomizations in 32 days.

VIEW ALL